Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

RenovoRx, Inc. - Common Stock (NQ:RNXT)

0.8396 -0.0804 (-8.74%)
Streaming Delayed Price Updated: 10:35 AM EDT, Aug 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about RenovoRx, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright’s 27th Annual Global Investment Conference in New York City, September 8-10, 2025
From RenovoRx, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Gapping stocks in Friday's session
The session on Friday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. 
Via Chartmill
Earnings Scheduled For August 14, 2025
 
Via Benzinga
Earnings Preview For RenovoRx
 
Via Benzinga
What's going on in today's pre-market session
Let's have a look at what is happening on the US markets before the opening bell on Friday. Below you can find the top gainers and losers in today's pre-market session. 
Via Chartmill
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
RenovoRx Revenue Jumps 28 Percent in Q2
Via The Motley Fool
Topics Intellectual Property
RenovoRx Inc. (NASDAQ:RNXT) Q2 2025 Earnings: Revenue Surpasses Estimates, Shares Climb on Positive Results
RenovoRx (NASDAQ:RNXT) Q2 2025 revenue beats estimates at $422K, shares rise 4.8%. RenovoCath adoption grows, Phase III trial progresses. Strong cash position supports operations. 
Via Chartmill
RenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on Interim Data Review
From RenovoRx, Inc.
Via Business Wire
RenovoRx Launches Multi-Center Post-Marketing Registry Study to Evaluate Cancer Treatment Delivered by RenovoCath® Device to Solid Tumors
From RenovoRx, Inc.
Via Business Wire
RenovoRx to Host Second Quarter 2025 Financial Results and Business Highlights Conference Call on August 14th at 4:30 p.m. ET
From RenovoRx, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights
From RenovoRx, Inc.
Via Business Wire
RenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21st
From RenovoRx, Inc.
Via Business Wire
Earnings Scheduled For May 15, 2025
 
Via Benzinga
U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy Platform
From RenovoRx, Inc.
Via Business Wire
RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET
From RenovoRx, Inc.
Via Business Wire
Johns Hopkins Medicine Initiates Patient Enrollment for RenovoRx’s Ongoing Phase III TIGeR-PaC Clinical Trial
From RenovoRx, Inc.
Via Business Wire
RenovoRx Increases U.S. Production of RenovoCath® Devices to Meet Growing Demand from Oncology Community
From RenovoRx, Inc.
Via Business Wire
These stocks are moving in today's pre-market session
The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10th
From RenovoRx, Inc.
Via Business Wire
RenovoRx Reports Initial Revenues from RenovoCath® Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial
From RenovoRx, Inc.
Via Business Wire
RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting
From RenovoRx, Inc.
Via Business Wire
RenovoRx Pre-Clinical Results Supporting TAMP™ as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting
From RenovoRx, Inc.
Via Business Wire
RenovoRx CEO to Provide Strategic Update During Fireside Chat on Thursday, April 3rd at 12:00 p.m. ET
From RenovoRx, Inc.
Via Business Wire
RenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025
From RenovoRx, Inc.
Via Business Wire
RenovoRx Advances Commercialization of RenovoCath® with Several New Purchase Orders, Including Customer Reorders
From RenovoRx, Inc.
Via Business Wire
RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP™ Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery
From RenovoRx, Inc
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.